Sotera Health (SHC) Q2 Revenue Up 6%

Sotera Health (NASDAQ:SHC), a global provider of sterilization and lab testing services to the healthcare and life sciences industries, reported its second quarter 2025 results on August 8, 2025. The Q2 2025 earnings release highlighted significant GAAP revenue and adjusted (non-GAAP) earnings beats, with GAAP revenue at $294 million compared to the $275.89 million analyst estimate, and adjusted earnings per share (EPS) at $0.20 versus the expected $0.17 (non-GAAP). The quarter showed continued strength across core businesses, particularly within the Sterigenics sterilization segment, prompting management to raise its outlook for FY2025. While GAAP net income was slightly lower than the prior year, Adjusted profitability improved. Overall, the quarter demonstrated operational momentum, stable customer demand, and progress on strategic priorities, tempered by ongoing legal settlement costs related to EO litigation. Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report. Sotera Health provides sterilization services, lab testing, and radioisotope supply through a network of 62 facilities worldwide. The company’s main customers are medical device and pharmaceutical manufacturers, for whom meeting regulatory requirements is essential. Its three main business segments are Sterigenics (sterilization services), Nordion (supplier of cobalt-60, or Co-60, for radiation sterilization), and Nelson Labs (lab testing for quality, safety, and regulatory compliance).Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool